News | January 06, 2026
Nia Therapeutics unveils first implantable brain interface for memory disorders
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
Topiramate is indicated as a treatment of epilepsy and migraine
The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 m
This is the second Ready-To-Use Infusion bag (RTU Bags) ANDA drug product approved for Caplin Steriles
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
CB03 is a candidate drug for the treatment of ALS and other central nerve system (CNS) diseases
Subscribe To Our Newsletter & Stay Updated
